NDANASALSPRAY
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
NEFFY (epinephrine) by ARS Pharmaceuticals is adrenergic alpha-agonists [moa]. Approved for anaphylaxis, cardiac arrest. First approved in 2024.
Drug data last refreshed 21h ago
Mechanism of Action
Adrenergic alpha-Agonists
Pharmacologic Class:
alpha-Adrenergic Agonist
Indications (2)
Clinical Trials (20)
Continuous Versus Bolus Norepinephrine Administration to Treat Postinduction Hypotension
Started Apr 2026
446 enrolled
Postinduction Hypotension
Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the Sclerotherapy of Leg Telangiectasias
Started Feb 2026
20 enrolled
Leg Veins
Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy
Started May 2025
600 enrolled
Allergic Reactions
Pneumatic Leg Compression and Norepinephrine Requirements in Patients Having Non-cardiac Surgery
Started May 2025
238 enrolled
Hypotension During Surgery
Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Started Apr 2025
186 enrolled
Intraoperative Bradycardia
Worked on NEFFY at ARS Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.